Literature DB >> 10521447

AML3/CBFalpha1 is required for androgen-specific activation of the enhancer of the mouse sex-limited protein (Slp) gene.

Y M Ning1, D M Robins.   

Abstract

A complex 120-base pair enhancer, derived from the mouse sex-limited protein (Slp) gene, is activated solely by the androgen receptor (AR) in specific tissues, although it contains a hormone response element recognized by several steroid receptors. The generation of this transcriptional specificity has been ascribed to the interactions of the receptor with tissue-specific nonreceptor factors bound to accessory sites within the enhancer. Protein-DNA interaction assays revealed two factors binding the 5' part of the enhancer that differ widely in abundance between cells showing AR-specific activation of the Slp element compared with those that also permit activation by glucocorticoid receptor (GR). The factor designated B formed a complex centered on the sequence TGTGGT, a core motif recognized by members of the AML/CBFalpha transcription factor family. This complex was competed by a high affinity binding site specific for AML/CBFalpha and was specifically supershifted by an antibody to AML3/CBFalpha1, placing factor B within the AML3/CBFalpha1 subclass. Interestingly, this factor was shown to bind to a second site in the 3' part of the enhancer, positioned between the two critical AR binding sites. Transfection studies revealed that AML1-ETO, a dominant-negative AML/CBFalpha construct, abrogated AR induction of the enhancer, but not of simple hormone response elements. Furthermore, overexpression of AML3/CBFalpha1 could rescue the AML1-ETO repression. Finally, glutathione S-transferase-AML/CBFalpha fusion proteins demonstrated direct interaction between AML/CBFalpha and steroid receptors. Although this interaction was equivalent between AML1/CBFalpha2 and AR or GR, AML3/CBFalpha1 showed stronger interaction with AR than with GR. These data demonstrate that AML3/CBFalpha1 is functionally required for hormonal induction of the Slp enhancer and that direct, preferential protein-protein interactions may contribute to AR-specific activation. These results demonstrate an intriguing role of AML3/CBFalpha1 in steroid- as well as tissue-specific activation of target genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521447     DOI: 10.1074/jbc.274.43.30624

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

Review 2.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein.

Authors:  Claire K Inman; Na Li; Paul Shore
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

4.  Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation.

Authors:  Sanjeev K Baniwal; Gillian H Little; Nyam-Osor Chimge; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

Review 5.  The epigenetic landscape of mammary gland development and functional differentiation.

Authors:  Monique Rijnkels; Elena Kabotyanski; Mohamad B Montazer-Torbati; C Hue Beauvais; Yegor Vassetzky; Jeffrey M Rosen; Eve Devinoy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-02-17       Impact factor: 2.673

6.  Discovering modulators of gene expression.

Authors:  Ozgün Babur; Emek Demir; Mithat Gönen; Chris Sander; Ugur Dogrusoz
Journal:  Nucleic Acids Res       Date:  2010-05-13       Impact factor: 16.971

7.  Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA.

Authors:  Sanjeev K Baniwal; Omar Khalid; Donna Sir; Grant Buchanan; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Endocrinol       Date:  2009-04-23

8.  Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors.

Authors:  Xiaodong Li; Luke H Hoeppner; Eric D Jensen; Rajaram Gopalakrishnan; Jennifer J Westendorf
Journal:  J Cell Biochem       Date:  2009-10-01       Impact factor: 4.429

Review 9.  The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.

Authors:  Bandana Chatterjee
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

10.  Runx2 regulates survivin expression in prostate cancer cells.

Authors:  Minyoung Lim; Chen Zhong; Shangxin Yang; Adam M Bell; Michael B Cohen; Pradip Roy-Burman
Journal:  Lab Invest       Date:  2009-11-30       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.